Analysts forecast that Amedisys Inc (NASDAQ:AMED) will report $0.85 earnings per share for the current quarter, according to Zacks. Six analysts have issued estimates for Amedisys’ earnings. The highest EPS estimate is $0.89 and the lowest is $0.82. Amedisys posted earnings per share of $0.56 in the same quarter last year, which suggests a positive year-over-year growth rate of 51.8%. The business is expected to issue its next quarterly earnings report on Wednesday, February 27th.
On average, analysts expect that Amedisys will report full year earnings of $3.58 per share for the current financial year, with EPS estimates ranging from $3.55 to $3.62. For the next year, analysts expect that the firm will post earnings of $4.04 per share, with EPS estimates ranging from $3.97 to $4.25. Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Amedisys.
Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, February 27th. The health services provider reported $0.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.06. Amedisys had a net margin of 5.39% and a return on equity of 23.27%. The company had revenue of $434.38 million for the quarter, compared to the consensus estimate of $427.75 million. During the same quarter in the prior year, the firm earned $0.56 earnings per share. Amedisys’s revenue was up 9.2% on a year-over-year basis.
Shares of NASDAQ AMED traded down $0.10 during mid-day trading on Friday, reaching $124.20. The company had a trading volume of 371,868 shares, compared to its average volume of 622,191. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.12. Amedisys has a 52 week low of $56.95 and a 52 week high of $140.91. The stock has a market cap of $4.11 billion, a PE ratio of 34.21, a PEG ratio of 1.70 and a beta of 1.43.
In other news, insider David L. Kemmerly sold 3,125 shares of the firm’s stock in a transaction dated Wednesday, December 12th. The stock was sold at an average price of $133.82, for a total value of $418,187.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider David B. Pearce sold 410 shares of the firm’s stock in a transaction dated Monday, December 24th. The stock was sold at an average price of $106.61, for a total value of $43,710.10. Following the completion of the transaction, the insider now owns 11,010 shares in the company, valued at $1,173,776.10. The disclosure for this sale can be found here. 2.60% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the company. First Hawaiian Bank raised its holdings in shares of Amedisys by 45.6% in the 4th quarter. First Hawaiian Bank now owns 415 shares of the health services provider’s stock worth $49,000 after purchasing an additional 130 shares during the period. Financial Gravity Companies Inc. purchased a new stake in shares of Amedisys during the 4th quarter valued at about $50,000. Meeder Asset Management Inc. raised its holdings in shares of Amedisys by 107.4% during the 4th quarter. Meeder Asset Management Inc. now owns 477 shares of the health services provider’s stock valued at $56,000 after buying an additional 247 shares during the period. Captrust Financial Advisors raised its holdings in shares of Amedisys by 161.8% during the 4th quarter. Captrust Financial Advisors now owns 597 shares of the health services provider’s stock valued at $70,000 after buying an additional 369 shares during the period. Finally, Group One Trading L.P. purchased a new stake in shares of Amedisys during the 4th quarter valued at about $90,000. Institutional investors own 92.15% of the company’s stock.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Featured Article: Why do companies pay special dividends?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.